Related Experiment Video

Updated: Jul 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Impact of carvedilol on the serum lipid profile

Randall P Sharp1, Riaz Sirajuddin, Imran M Sharief

  • 1College of Pharmacy, Southwestern Oklahoma State University, Weatherford, OK 73096, USA. randall.sharp@swosu.edu

The Annals of Pharmacotherapy
|March 28, 2008
PubMed

Insights

Carvedilol appears to improve lipid profiles compared to beta(1)-selective antagonists, especially in patients with heart failure or hypertension and dyslipidemia. However, its independent effects on lipids require further investigation.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Lipid Metabolism

Background:

  • Dyslipidemia is a significant risk factor for cardiovascular disease.
  • Beta-blockers can impact serum lipid profiles, influencing treatment decisions.
  • Carvedilol is a non-selective beta-blocker with alpha-blocking activity used for heart failure and hypertension.

Purpose of the Study:

  • To systematically review existing evidence on the effects of carvedilol on serum lipid profiles.
  • To compare carvedilol's lipid effects with other antihypertensive agents, particularly beta(1)-selective antagonists.
  • To assess carvedilol's independent impact on cholesterol and triglyceride levels.

Main Methods:

  • Comprehensive literature searches of MEDLINE and International Pharmaceutical Abstracts (1966-2007).
  • Inclusion of published studies and case reports evaluating carvedilol's impact on lipid profiles.
  • Exclusion of studies on off-label use or small pilot trials (e.g., 10 patients).

Main Results:

  • Carvedilol demonstrated significant improvement in lipid profiles in 4 out of 12 reviewed studies.
  • Compared to other antihypertensive medications, carvedilol showed a significantly better or neutral lipid profile in 3 out of 4 comparative studies.
  • Beta(1)-selective antagonists were shown to worsen lipid profiles when compared to carvedilol.

Conclusions:

  • Carvedilol is a favorable treatment option for patients with heart failure and/or hypertension who also have dyslipidemia.
  • Carvedilol exhibits a superior lipid profile compared to beta(1)-selective antagonists.
  • Further research is needed to definitively establish carvedilol's independent effects on serum lipids.
Abstract

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Time Course of Drug Effect01:14

Time Course of Drug Effect

The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50 percent of...